Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | IDE | P14735 | 1/20 | 0.34 |
| ▸ | MYC | P01106 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1355391 | 0.78 | ALDH1A1 (0.52) | CLCN2ALDH1A1ALOX15HSD17B10KDM4E | |
| SCHEMBL9420612 | 0.78 | GABRA1 (0.34) | CYP3A4GABRA1GABRB2ALDH1A1HPGD | |
| SCHEMBL3765835 | 0.78 | CYP3A4 (0.66) | CYP3A4ALDH1A1ALOX15HSD17B10KDM4E | |
| SCHEMBL2347924 | 0.78 | GABRA1 (0.60) | CYP3A4GABRA1GABRB2ALDH1A1HPGD | |
| SCHEMBL4687669 | 0.77 | ALDH1A1 (0.52) | CYP3A4ALDH1A1ALOX15KDM4EHPGD | |
| SCHEMBL4705523 | 0.76 | CYP3A4 (0.57) | CYP3A4GABRA1GABRB2ALDH1A1HSD17B10 | |
| SCHEMBL10594316 | 0.76 | CYP3A4 (0.47) | CYP3A4GABRA1GABRB2ALDH1A1ALOX15 | |
| Methane SCHEMBL5177350 | 0.75 | ALDH1A1 (0.50) | CYP3A4ALDH1A1ALOX15KDM4EHPGD | |
| Hydrochloric Acid SCHEMBL10392666 | 0.75 | ALDH1A1 (0.50) | CYP3A4ALDH1A1ALOX15KDM4EHPGD | |
| SCHEMBL5113652 | 0.75 | GABRA1 (0.68) | GABRA1GABRB2CLCN2ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2026-01-20 | — | — | US | claimed |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-11-09 | — | — | US | claimed |
| CN-102164900-A | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives | HOFFMANN LA ROCHE | 2011-08-24 | — | — | CN | disclosed |
| EP-1436291-B1 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA SA (FR) | 2009-01-14 | — | — | EP | disclosed |
| US-20070238734-A1 | JNK INHIBITORS | SANOLI-AVENTIS (FR) | 2007-10-11 | — | — | US | disclosed |
| EP-1453852-B1 | SELECTIVE UROKINASE INHIBITORS | WILEX AG (DE) | 2007-01-17 | — | — | EP | disclosed |
| US-7148215-B2 | Prodrugs as antihistamines or anticarcinogenic agents | AVENTIS PHARMA S.A. (FR) | 2006-12-12 | — | — | US | disclosed |
| EP-1317430-B1 | (2-AZABICYCLO [2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2005-05-18 | — | — | EP | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | TRIAD THERAPEUTICS, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | AVENTIS PHARMA S.A, (FR) | 2005-01-13 | — | — | US | disclosed |
| EP-1436291-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | Aventis Pharma S.A. (FR) | 2004-07-14 | — | — | EP | disclosed |
| EP-1317430-A1 | (2-AZABICYCLO 2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GmbH (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2003024967-A2 | INDOLIZINES AS KINASE PROTEIN INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2003-03-27 | — | — | WO | disclosed |
| WO-2002022578-A1 | (2-AZABICYCLO[2.2.1]HEPT-7-YL)METHANOL DERIVATIVES AS NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | MERCK PATENT GMBH (DE) | 2002-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050019825-A9 | Common ligand mimics: pseudothiohydantoins | FGFR3, BID, FLT3 | CYP3A4 846/4885GABRA1 361/4885GABRB2 567/4885 |
| US-20230357165-A1 | QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF | ATG7, GOT1, LIPC | CYP3A4 433/4885GABRA1 2687/4885GABRB2 3139/4885 |
| US-20070238734-A1 | JNK INHIBITORS | MAP3K7, MAPKAPK2, MAPK7 | CYP3A4 1524/4885GABRA1 4303/4885GABRB2 3687/4885 |
| US-20050009831-A1 | Pyrrolo[1,2-a]pyrazine-8-carboxamides are JNK inhibitors, useful as anticarcinogenic agents | CNKSR1, ROS1, NRAS | CYP3A4 1900/4885GABRA1 2801/4885GABRB2 2210/4885 |
| US-12528777-B2 | Quinazolinones derivatives for treatment of non-alcoholic fatty liver disease, preparation and use thereof | ATG7, GOT1, ULK1 | CYP3A4 947/4885GABRA1 3104/4885GABRB2 2871/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | CYP3A4 784/4885GABRA1 484/4885GABRB2 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.